Combination of Novel Therapies for CKD Comorbid Depression
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 201 participants.
Also called NCT04422652
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 201 participants
- Registry
-
NCT04422652
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04422652. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-24 (actual); primary completion 2026-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combination of Novel Therapies for CKD Comorbid Depression
- Acronym
- CONCORD
- Condition
- Chronic Kidney Diseases
- Condition
- Major Depressive Disorder
- Condition
- End Stage Kidney Disease (ESRD)
- Intervention (Drug)
- Bupropion
- Intervention (Behavioral)
- Behavioral activation therapy
- Intervention (Drug)
- Placebo
- Intervention (Other)
- Clinical Management
- Lead sponsor
- Stony Brook University
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct04422652- Content hash
f1543ede7a13af90f490853c12ac4328c8408f2b0cc06bd19e64470a5ea113a4